GB2198352A - Aqueous ethanolic compositions of ranitidine - Google Patents
Aqueous ethanolic compositions of ranitidine Download PDFInfo
- Publication number
- GB2198352A GB2198352A GB08728957A GB8728957A GB2198352A GB 2198352 A GB2198352 A GB 2198352A GB 08728957 A GB08728957 A GB 08728957A GB 8728957 A GB8728957 A GB 8728957A GB 2198352 A GB2198352 A GB 2198352A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- ranitidine
- composition according
- formulation
- free base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 33
- 229960000620 ranitidine Drugs 0.000 title claims description 20
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical group [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 title claims description 20
- 238000009472 formulation Methods 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000013011 aqueous formulation Substances 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 6
- 239000000337 buffer salt Substances 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 2
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- YFDUWSBGVPBWKF-UHFFFAOYSA-N Butyl salicylate Chemical class CCCCOC(=O)C1=CC=CC=C1O YFDUWSBGVPBWKF-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- -1 alkyl hydroxybenzoates Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 108010011222 cyclo(Arg-Pro) Proteins 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Description
v A 2198352 1 - PHARMACEUTICAL COMPOSITIONS 1 1 The present invention
relates to a pharmaceutical composition containing as active ingredient the histamine H2 antaoonist ranitidine.
Ranitidine, [N-[2-[[[5-(dimethylamino)methyl-2-furanyllmethyllthiolethyllN'-methyl-2-nitro-1,1-ethenediamine, and its physiologically acceptable salts are described in British Patent Specification No. 1565966. In that specification there is reference to liquid formulations for oral and parenteral administrations and there is a description of an aqueous based formulation for intravenous use and another of an oral syrup. Both of these formulations contained sufficient hydrochloric acid to achieve a pH of 5.0 and 'the syrups also contained SorlDitol solution BPC and a fiavour as required.
British Patent Application No. GB 2142820A describes aaueous based formulations containinq ranitidine and/or one or more of its physiologically acceptable salts thereof having a pH within the ranQe 6.57.5. In that specification there is reference to liquid formulations for oral and parenterai administration and there are examples of aoueous formulations for intravenous and oral use. These formulations contain ranitidine hyrochloride and are buffered to a pH of approximately 7 and for intravenous administration the formulations also contain phenol or sodium chloride. For oral administration the formulation also contains hydroxyproDylmethyl cellulose as a viscosity enhancing agent, a preservative (parabens), a sweetening aaent and a flavour. These compositions have a significantly oreater shelf-iife over those in British Patent No. 1565966.
We have now surprisinqly found that the stability of ranitidine in aqueous based formulations and more particularly aqueous based formulations for oral administration may be substantially enhanced by the addition of ethanol to the formulation.
Thus the present invention provides a pharmaceutical composition which is an aqueous formulation of ranitidine and/or one or more physioloqically acceptable salts thereof also containing ethanol. The aqueous formulation is prepared using ingredients of a purity such that it is suitable for administration to patients and will in qeneral 2 contain at least one conventional pharmaceutical excipient in addition to the ethanol and ranitidine and/or physiolooically acceptable salts thereof.
The amount of ethanol present in the formulation is such that the resulting formulation has the enhanced stability. Preferably the amount of ethanol in the composition on a weiaht/volume basis of the complete formulation, is within the ranae 2.5'0 to 10'0, and more particularly is between 5 to 1000 w/v, more esoecially 7-8% w/v.
Preferred compositions according to the invention are those in which the pH of the aoueous formulation is within the ranoe 6.5 to 7.5, particularly 6.8 to 7.4 and more especially 7 to 7.3. The required pH of the formulation is preferably obtained by the use of suitaoie Duffer salts for example, potassium oinydroqen orthophosphate and disocium hydroqen orthophosph2te or citric acid and disodium hydroQen ortnophosphate.
A preferred emoodiment of the invention is an aQueous formulation for oral administration. Such a fo:-mulation may comprise ranitidine and/or one or more of its physiolocically acceptable salts dissolved in water, ethanol, a preservative and a viscosity enh2ncinQ 2qent. Preferably the reouired pH of the formulation is obtained by the use Of appropriate buffer salts. Optionally the composition may also contain other conventional excioients such as 2 sweetener, a fiavour and/or flavourina aids.
Examples of suitable preservatives include one or more alkyl hydroxybenzoates such as methyl, ethyl, propyl and/or butyl hydroxybenzoates.
Examples of suitable viscosity enhancino aaents include Xanthan gum; sorbitol; glycerol; sucrose; or a cellulose derivative such as carboxymethy1cellulose or a salt thereof or a CI-4 alkyi and/or a hydrOXYC2-4alkyl ether of cellulose such as methylcelluiose, ethylceliulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose and hyaroxypropylmethylcellulose.
Examples of suitable sweeteners include saccharin sodium, sodium cyclamate, soroitol and sucrose.
Examples of suitable flavouring agents include 'mint' flavours such as peppermint flavouring agents.
1 1 t i 11 - 3 The concentration of ranitidine in the oral formulation, expressed as free base, is conveniently within the range 20-400mg per 10mi, for example 20-200 mQ per 10mi, more particularly 150mq per 10ml dose.
The amount of ethanol in the formulation for oral administration, expressed as a percentage of the complete formulation on a weiqht/volume basis, is preferably within the r2noe 2.5 to 10'50, and more particularly between 5 to 10%, more especially 7-8,o.
The amount of viscosity enhancina aaent in the formulation will preferably be sufficient to give a solution with a viscosity in the ranqe of 10 to 100 centipoises.
The aoueous formulations for oral administration are conveniently prepared by mixinQ an aqueous solution of ranitidine and/or one or more of its physiologically acceotaole salts together with ethanol and the excipients, with aqueous solution_or dispersion of the viscosity enhancing agent.
The aqueous formulations accoroinq to the invention are preferably prepared using ranitidine in the form of its hydrochloride sait.
An illustrative example of a formulation accordino to the invention is as follows. In this example the relative proportions of ranitidine hydrochloride and the buffer salts are such that the formulation has a pH of approximately 7.
Ranitidine oral liquid formulation (150ma/10m1) expressed as free base % w/v Ranitidine hydrochloride 1.68 Ethanol 7.5 Potassium dihydrogen orthophosphate 0.095 Disodium hydroqen orthophosphate anhydrous 0.350 Hydroxypropylmethylcellulose qs Preservative qs Sweetening agents qs Flavour qs Purified water BP to 100M1
Claims (1)
1. A pharmaceutical composition which is an aqueous formulation of ranitidine and/or one or more physiologically acceptable salts thereof, said formulation also containing ethanol.
11 2. A pharmaceutical composition according to claim 1 containing 2.5% to 10% weight/volume ethanol based on the complete formulation.
3. A pharmaceutical composition according to claim 1 containing 7% to 8% weight/volume ethanol based on the complete formulation.
4. A pharmaceutical composition according to claim 1 having a pH in the range 6.5 to 7.5.
5. A pharmaceutical composition according to claim 1 having a pH in the range 6.8 to 7.4.
6. A pharmaceutical composition according to claim 1 having a pH in the range 7.0 to 7.3.
7. A pharmaceutical composition according to claim 1 wherein said pH is obtained by the use of buffer salts.
8. A pharmaceutical composition as claimed in claim 1 suitable for oral administration.
9. A pharmaceutical composition as claimed in claim 8 containing 20-400 mg ranitidine per 10 inl dose expressed as free base.
10. A pharmaceutical composition according to claim 8 containing 20-200 mg ranitidine per 10 ml dose expressed as free base.
J 11. A pharmaceutical composition according to claim 8 containing 150 mg ranitidine per 10 ml dose expressed as 5 free base.
j 12. A pharmaceutical composition according to claim 1 prepared using ranitidine in the form of the hydrochloride salt.
13. A pharmaceutical composition which is an aqueous formulation of ranitidine suitable for oral administration containing 150 mg ranitidine per 10 ml dose expressed as free base, said formulation having a pH in the range 7.0 to 7.3 and also containing 7% to 8% weight/volume ethanol based on the complete formulation.
14. A pharmaceutical composition according to claim 13 wherein said pH is obtained by the use of buffer salts.
Published 1988 st The Patent Office, State House, 66!71 High Holborn, London WC1R 4TP. Further copies Tuay be obtained from The Patent Offtce, Sales Branch, St Mary Cray. Orpington, Kent BR5 3RD. Printed by Multiplex techniques ltd, St Mary Cray, Kent. Con- 1/87.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868629781A GB8629781D0 (en) | 1986-12-12 | 1986-12-12 | Pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB8728957D0 GB8728957D0 (en) | 1988-01-27 |
| GB2198352A true GB2198352A (en) | 1988-06-15 |
| GB2198352B GB2198352B (en) | 1990-11-28 |
Family
ID=10608930
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB868629781A Pending GB8629781D0 (en) | 1986-12-12 | 1986-12-12 | Pharmaceutical compositions |
| GB8728957A Expired - Lifetime GB2198352B (en) | 1986-12-12 | 1987-12-11 | Pharmaceutical compositions containing ranitidine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB868629781A Pending GB8629781D0 (en) | 1986-12-12 | 1986-12-12 | Pharmaceutical compositions |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5068249A (en) |
| JP (1) | JP2590156B2 (en) |
| KR (1) | KR960008228B1 (en) |
| AT (1) | AT395373B (en) |
| AU (1) | AU607451B2 (en) |
| BE (1) | BE1000624A5 (en) |
| CA (1) | CA1303993C (en) |
| CH (1) | CH675207A5 (en) |
| CZ (1) | CZ281599B6 (en) |
| DE (1) | DE3742127C2 (en) |
| DK (1) | DK167842B1 (en) |
| FR (1) | FR2608921B1 (en) |
| GB (2) | GB8629781D0 (en) |
| HK (1) | HK19095A (en) |
| IE (1) | IE60618B1 (en) |
| IL (1) | IL84795A0 (en) |
| IT (1) | IT1211967B (en) |
| NL (1) | NL194431C (en) |
| NZ (1) | NZ222879A (en) |
| PH (1) | PH25390A (en) |
| SE (1) | SE504333C2 (en) |
| YU (1) | YU46561B (en) |
| ZA (1) | ZA879338B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0431759A1 (en) * | 1989-11-10 | 1991-06-12 | Glaxo Group Limited | Process for the preparation of a ranitidine resin absorbate |
| WO1996001129A1 (en) * | 1994-07-06 | 1996-01-18 | Farmarc Nederland B.V. | Inclusion complexes of ranitidine |
| WO1999004788A1 (en) * | 1997-07-23 | 1999-02-04 | Glaxo Group Limited | Aqueous compositions comprising ranitidine and lcmt sucrose |
| GR1009069B (en) * | 2015-01-05 | 2017-07-07 | Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. | Drinkable pharmaceutical high-concentration solutions containing hydrochloric ranitidine |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019875D0 (en) * | 1990-09-11 | 1990-10-24 | Glaxo Group Ltd | Pharmaceutical compositions |
| US5169864A (en) * | 1991-11-15 | 1992-12-08 | Baxter International Inc. | Unbuffered premixed ranitidine formulation |
| WO1995010274A1 (en) * | 1993-10-14 | 1995-04-20 | F.H. Faulding & Co. Limited | Aqueous pharmaceutical composition |
| US5407687A (en) * | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
| HU213598B (en) * | 1994-10-18 | 1997-08-28 | Ge Lighting Tungsram Rt | One-side socketed discharge lamp |
| US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| US5976578A (en) * | 1996-10-10 | 1999-11-02 | Mcneil-Ppc, Inc. | Liquid antacid compositions |
| KR100412290B1 (en) * | 2001-11-27 | 2003-12-31 | 주식회사 동구제약 | Composition of suspension containing ranitidine and its manufacturing process |
| US20060100271A1 (en) * | 2004-11-08 | 2006-05-11 | Keith Whitehead | Stabilized aqueous ranitidine compositions |
| NZ574331A (en) * | 2006-07-21 | 2011-01-28 | Lyne Lab | Liquid compositions of calcium acetate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
| GB2142820A (en) * | 1983-05-13 | 1985-01-30 | Glaxo Group Ltd | Aqueous compositions of ranitidine |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2735587A1 (en) * | 1977-08-06 | 1979-02-15 | Sandoz Ag | STABLE SOLUTIONS AND METHOD FOR THEIR PRODUCTION |
| IL63968A (en) * | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| DE3108753A1 (en) * | 1981-03-07 | 1982-09-16 | Degussa Ag, 6000 Frankfurt | Substituted alkylphenylsulphonylguanidines with a heterocyclic radical |
| SE8302689L (en) * | 1982-05-14 | 1983-11-15 | Richter Gedeon Vegyeszet | PHARMACEUTICAL COMPOSITIONS CONTAINING MULTIPLE ACTIVE INGREDIENTS |
| JPS59101478A (en) * | 1982-11-29 | 1984-06-12 | Sunstar Inc | Water-based composition compounded stably with ligustilide |
| SE8704436D0 (en) * | 1987-11-13 | 1987-11-13 | Pm Konsult Handelsbolag | USE OF ANTI-SECRETARY SUBSTANCES FOR NEW INDICATIONS |
-
1986
- 1986-12-12 GB GB868629781A patent/GB8629781D0/en active Pending
-
1987
- 1987-12-11 GB GB8728957A patent/GB2198352B/en not_active Expired - Lifetime
- 1987-12-11 DE DE3742127A patent/DE3742127C2/en not_active Expired - Lifetime
- 1987-12-11 DK DK652787A patent/DK167842B1/en not_active IP Right Cessation
- 1987-12-11 NL NL8703000A patent/NL194431C/en not_active IP Right Cessation
- 1987-12-11 AT AT0327387A patent/AT395373B/en not_active IP Right Cessation
- 1987-12-11 AU AU82444/87A patent/AU607451B2/en not_active Expired
- 1987-12-11 IE IE336787A patent/IE60618B1/en not_active IP Right Cessation
- 1987-12-11 ZA ZA879338A patent/ZA879338B/en unknown
- 1987-12-11 YU YU224587A patent/YU46561B/en unknown
- 1987-12-11 FR FR878717295A patent/FR2608921B1/en not_active Expired - Lifetime
- 1987-12-11 CH CH4842/87A patent/CH675207A5/fr not_active IP Right Cessation
- 1987-12-11 SE SE8704952A patent/SE504333C2/en not_active IP Right Cessation
- 1987-12-11 PH PH36204A patent/PH25390A/en unknown
- 1987-12-11 JP JP62312419A patent/JP2590156B2/en not_active Expired - Fee Related
- 1987-12-11 CA CA000554086A patent/CA1303993C/en not_active Expired - Lifetime
- 1987-12-11 KR KR1019870014136A patent/KR960008228B1/en not_active IP Right Cessation
- 1987-12-11 NZ NZ222879A patent/NZ222879A/en unknown
- 1987-12-11 BE BE8701417A patent/BE1000624A5/en not_active IP Right Cessation
- 1987-12-11 IL IL84795A patent/IL84795A0/en not_active IP Right Cessation
- 1987-12-11 IT IT8748698A patent/IT1211967B/en active
-
1990
- 1990-03-14 US US07/494,804 patent/US5068249A/en not_active Expired - Lifetime
-
1991
- 1991-12-23 CZ CS914037A patent/CZ281599B6/en not_active IP Right Cessation
-
1995
- 1995-02-09 HK HK19095A patent/HK19095A/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
| GB2142820A (en) * | 1983-05-13 | 1985-01-30 | Glaxo Group Ltd | Aqueous compositions of ranitidine |
Non-Patent Citations (2)
| Title |
|---|
| GB THE PHARMACEUTICAL CODEX 11TH EDITION (1979) PAGE 15 * |
| US THE MARCK MANUAL 14TH EDITION (1982) PAGE 2301 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0431759A1 (en) * | 1989-11-10 | 1991-06-12 | Glaxo Group Limited | Process for the preparation of a ranitidine resin absorbate |
| WO1996001129A1 (en) * | 1994-07-06 | 1996-01-18 | Farmarc Nederland B.V. | Inclusion complexes of ranitidine |
| WO1999004788A1 (en) * | 1997-07-23 | 1999-02-04 | Glaxo Group Limited | Aqueous compositions comprising ranitidine and lcmt sucrose |
| US6265449B1 (en) | 1997-07-23 | 2001-07-24 | Glaxo Wellcome Inc. | Aqueous compositions comprising ranitidine and LCMT sucrose |
| GR1009069B (en) * | 2015-01-05 | 2017-07-07 | Λαμδα Φαρμακευτικα Εργαστηρια Εφαρμοσμενης Ερευνας & Αναπτυξης Α.Ε. | Drinkable pharmaceutical high-concentration solutions containing hydrochloric ranitidine |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4585790A (en) | Pharmaceutical compositions | |
| GB2198352A (en) | Aqueous ethanolic compositions of ranitidine | |
| US20090048344A1 (en) | Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid | |
| US5498426A (en) | Liquid antacid compositions | |
| MXPA97002456A (en) | Liquid antiacidal compositions containing calcium carbonate and possibly simeticone as active compounds and monobasic potassium phosphate and potassium bicarbonate as regula | |
| CA1333773C (en) | Antitussive liquid compositions containing phenol | |
| IL31858A (en) | Concentrated liquid antacid compositions | |
| US4594359A (en) | Pharmaceutical compositions | |
| US20060100271A1 (en) | Stabilized aqueous ranitidine compositions | |
| US6265449B1 (en) | Aqueous compositions comprising ranitidine and LCMT sucrose | |
| WO1995010274A1 (en) | Aqueous pharmaceutical composition | |
| US5770618A (en) | Method for increasing the solubility of clemastine and pharmaceutical compositions prepared therefrom | |
| US20060127472A1 (en) | Taste-masked prednisolone oral formulations | |
| IE49218B1 (en) | Methyldopa composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE20 | Patent expired after termination of 20 years |
Effective date: 20071210 |